Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.
作者信息
Saburi Masuho, Okuhiro Kazuki, Yoshida Natsumi, Haruyama Takami, Moroga Yui, Yanai Yuka, Itani Kazuhito, Takano Kuniko, Honda Shuhei, Ono Keiji, Iwanaga Manami, Sasaki Hitohiro, Abe Miyuki, Kohno Kazuhiro, Nakayama Toshiyuki, Ohtsuka Eiichi, Ogata Masao
机构信息
Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
Department of Hematology, Oita University Hospital, Oita, Japan.
出版信息
J Clin Exp Hematop. 2023 Sep 28;63(3):197-200. doi: 10.3960/jslrt.23015. Epub 2023 Jul 28.
Abstract
摘要
相似文献
1
Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.未治疗的滤泡性淋巴瘤中与苯达莫司汀和抗CD20抗体相关的感染：一项真实世界研究。
J Clin Exp Hematop. 2023 Sep 28;63(3):197-200. doi: 10.3960/jslrt.23015. Epub 2023 Jul 28.
2
Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.苯达莫司汀暴露对滤泡性淋巴瘤患者接受苯达莫司汀与利妥昔单抗联合治疗后淋巴细胞减少风险的临床影响：一项单机构回顾性研究
Ann Hematol. 2022 Jan;101(1):209-211. doi: 10.1007/s00277-020-04388-6. Epub 2021 Jan 3.
3
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.由于严重血液学和感染性毒性，苯达莫司汀、米托蒽醌和利妥昔单抗用于未经治疗的高危滤泡性淋巴瘤患者的II期研究提前终止。
Br J Haematol. 2016 Nov;175(3):531-533. doi: 10.1111/bjh.13863. Epub 2015 Dec 18.
4
Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.一名接受苯达莫司汀和利妥昔单抗治疗的滤泡性淋巴瘤患者发生迟发性爱泼斯坦-巴尔病毒相关淋巴增殖性疾病
Ann Hematol. 2015 Dec;94(12):2061-2. doi: 10.1007/s00277-015-2463-3. Epub 2015 Aug 4.
5
The emerging role of bendamustine in follicular lymphoma.苯达莫司汀在滤泡性淋巴瘤中的新作用。
Leuk Lymphoma. 2009 Mar;50(3):317-8. doi: 10.1080/10428190902741497.
6
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).多中心、开放标签、Ⅱ期研究：苯达莫司汀和利妥昔单抗联合 90 钇（Y）替伊莫单抗替西他滨治疗未经治疗的滤泡性淋巴瘤（Fol-BRITe）。
Clin Cancer Res. 2019 Oct 15;25(20):6073-6079. doi: 10.1158/1078-0432.CCR-18-3755. Epub 2019 Jun 26.
7
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.在 GALLIUM 研究中，奥滨尤妥珠单抗或利妥昔单抗联合化疗治疗初治滤泡性淋巴瘤：化疗对疗效和安全性的影响。
J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
8
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.利妥昔单抗联合苯达莫司汀作为免疫化疗后进展的滤泡性淋巴瘤患者二线治疗的疗效：西班牙淋巴瘤肿瘤学组的一项II期试验
Leuk Lymphoma. 2019 Jun;60(6):1576-1579. doi: 10.1080/10428194.2018.1542147. Epub 2018 Dec 5.
9
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.苯达莫司汀联合利妥昔单抗对比 R-CHOP 一线治疗 3A 级滤泡性淋巴瘤患者：一项多中心回顾性研究的证据。
Oncologist. 2018 Apr;23(4):454-460. doi: 10.1634/theoncologist.2017-0037. Epub 2018 Jan 9.
10
Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database.基于 JADER 数据库的苯达莫司汀联合抗 CD20 抗体的细胞巨化病毒发生率和发病时间分析。
In Vivo. 2024 Mar-Apr;38(2):923-927. doi: 10.21873/invivo.13520.
引用本文的文献
1
Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database.基于 JADER 数据库的苯达莫司汀联合抗 CD20 抗体的细胞巨化病毒发生率和发病时间分析。
In Vivo. 2024 Mar-Apr;38(2):923-927. doi: 10.21873/invivo.13520.
本文引用的文献
1
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group.奥妥珠单抗联合化疗用于初治滤泡性淋巴瘤患者的早期疗效和安全性：波兰淋巴瘤研究组的一项真实世界回顾性报告
Adv Clin Exp Med. 2023 Jan;32(1):131-136. doi: 10.17219/acem/157290.
2
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases.奥妥珠单抗化疗联合方案在新冠疫情期间一线治疗滤泡性非霍奇金淋巴瘤中的疗效与安全性：克罗地亚血液疾病合作组KROHEM的一项研究
Hemasphere. 2022 Nov 15;6(12):e807. doi: 10.1097/HS9.0000000000000807. eCollection 2022 Dec.
3
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.在 GALLIUM 研究中，奥滨尤妥珠单抗或利妥昔单抗联合化疗治疗初治滤泡性淋巴瘤：化疗对疗效和安全性的影响。
J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
4
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.奥滨尤妥珠单抗用于滤泡性淋巴瘤的一线治疗。
N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.
5
Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.接受苯达莫司汀治疗的复发或难治性低度B细胞淋巴瘤患者的巨细胞病毒性视网膜炎
Ann Hematol. 2017 Jul;96(7):1215-1217. doi: 10.1007/s00277-017-3005-y. Epub 2017 Apr 26.
6
Bendamustine associated immune suppression and infections during therapy of hematological malignancies.苯达莫司汀在血液系统恶性肿瘤治疗期间相关的免疫抑制及感染
Leuk Lymphoma. 2016;57(3):512-9. doi: 10.3109/10428194.2015.1110748. Epub 2015 Dec 23.
7
Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.苯达莫司汀治疗低度B细胞淋巴瘤患者时的巨细胞病毒再激活
Ann Hematol. 2015 Mar;94(3):515-7. doi: 10.1007/s00277-014-2182-1. Epub 2014 Aug 10.
8
Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.以苯达莫司汀为基础的疗法作为非霍奇金淋巴瘤的一线治疗方案。
Med Oncol. 2014 May;31(5):944. doi: 10.1007/s12032-014-0944-1. Epub 2014 Apr 22.
9
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.利妥昔单抗与观察等待策略在晚期无症状非大肿块滤泡淋巴瘤患者中的比较：一项开放标签随机 3 期试验。
Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4.
10
Bendamustine: role and evidence in lymphoma therapy, an overview.苯达莫司汀：淋巴瘤治疗中的作用与证据概述
Leuk Lymphoma. 2014 Jul;55(7):1471-8. doi: 10.3109/10428194.2013.842986. Epub 2014 Feb 4.
Zotero 插件